Key takeaways
- ENDO-205 is an investigational peptide built to act on endometriosis lesions directly, without changing hormone levels.
- The FDA cleared its Investigational New Drug (IND) application in March 2026, which allows a first phase 1 study. It is not FDA-approved.
- Everything known about how well it works comes from the developer's animal studies and grant summaries. None of it is peer reviewed yet.
- There is no human efficacy or safety data, and we found no registered trial on ClinicalTrials.gov.
In March 2026, EndoCyclic Therapeutics announced that the FDA had cleared its IND for ENDO-205, a peptide it describes as a first-in-class, non-hormonal treatment for endometriosis 12. That headline has been travelling around peptide forums, so it's worth being clear about what it does and doesn't mean.
An IND clearance means the FDA is satisfied that a first human study can begin. It is not a verdict on whether the drug works. ENDO-205's story so far is a decade of grant-funded lab work, a company press release, and a lot of open questions.
What ENDO-205 is designed to do
ENDO-205 is a peptide designed to bind a downstream component of a signaling pathway that drives endometriosis lesions to migrate and invade surrounding tissue. The developer reports that it is absorbed primarily in endometriosis tissue rather than spread evenly through the body 3.
The company has not publicly named the target. An interview with founder Tanya Petrossian describes the peptide as engineered for selective uptake into endometriotic cells, where it triggers programmed cell death (apoptosis) and the immune system clears what's left 4.
The early NIH grant from 2019 describes the starting point as a panel of macrocyclic peptides (ring-shaped peptides, which tend to resist breakdown better than straight-chain ones) that were then optimized toward a more drug-like profile 5. Its half-life in people is unknown.
How that differs from today's treatments
Current management of endometriosis leans on three tools: pain relief, hormonal therapy and surgery 34. Hormonal options, including pills and GnRH antagonists that induce a temporary "medical menopause", mainly suppress symptoms and come with side effects that many people find hard to live with 3.
Surgery can bring relief, but lesions often return. The NIH grant summaries note a high chance of recurrence within five years of excision 35, and a trade-press feature reports that many patients are back to baseline within one to five years, partly because microscopic lesions are hard to see and remove 4.
ENDO-205's pitch is different on both fronts. It is meant to leave hormones alone, and to shrink or remove lesions rather than quiet symptoms. The 2025 grant summary states that in animal work it led to lesion regression "without altering estrous cyclicity", meaning the animals' reproductive cycles kept going normally 3. If that held up in people, it would be a genuinely new kind of treatment. That is a big if.
What has actually been shown
Here is the honest inventory, as of late October 2026:
- Peer-reviewed papers: we found none. A PubMed search for the founder's name with endometriosis returned no results.
- Animal and lab data: reported by the company. Its press release says ENDO-205 eliminated lesions and associated inflammation in preclinical studies, with no safety signals in GLP toxicology studies 1. The underlying data haven't been published for outside scientists to check.
- Funding: the program has been backed by a series of NIH small-business (SBIR) grants from NICHD since 2019, under the company's earlier name, EndoMet Biosciences 35. The latest, a Commercialization Readiness Pilot award running to March 2027, was meant to pay for clinical-grade manufacturing and the remaining safety tests needed for an IND 3. Grants fund work; they are not findings.
- Regulatory: IND cleared in March 2026, with a planned phase 1 study in healthy premenopausal women of reproductive age 12.
The site rates ENDO-205 at evidence level 2: preclinical animal studies only, no human efficacy data.
What we don't know yet
The open questions are the ones that matter most to anyone living with endometriosis:
- Does it work in humans? Mouse models of endometriosis don't always predict human results, and the first study is in healthy volunteers, so it won't answer this.
- Is it safe in humans? Clean animal toxicology is a prerequisite for a trial, not proof of safety.
- Does it help pain or fertility? The company hopes so, but no data on either exist in people.
- How is it given, and how often? Not disclosed. The founder has suggested continued dosing may not be needed once lesions start resolving, but that comes from animal work 4.
- When will results arrive? Unknown. We found no ENDO-205 entry on ClinicalTrials.gov when we checked.
Early-stage drugs fail often, usually for reasons nobody saw coming in the lab. A promising mechanism and a cleared IND are the start of the process, not the middle.
Why this one is still worth watching
Endometriosis affects roughly 10% of women and girls of reproductive age, and diagnosis takes an average of 4 to 12 years 23. There is no approved treatment that stops or reverses the disease itself 4. A drug that targets lesions without hormones would fill a real gap, which is why this IND got attention.
The company is also developing FemLUNA, an imaging agent meant to spot lesions without surgery 12. It's a separate product, but it speaks to the same problem: lesions are hard to find and hard to treat.
The bottom line
ENDO-205 is an interesting, NIH-funded idea that has just cleared the first regulatory hurdle for human testing. Every claim about lesion elimination so far comes from the developer's own animal work, unpublished and unreplicated. Until phase 1 results and peer-reviewed data appear, it is a research program, not a treatment.
This is educational information, not medical advice.
Sources
- EndoCyclic Therapeutics announces FDA clearance of Investigational New Drug (IND) application for ENDO-205 (company press release) — Drug Discovery Online, March 23, 2026. https://www.drugdiscoveryonline.com/doc/endocyclic-therapeutics-announces-fda-clearance-investigational-new-drug-ind-application-0001
- FDA clears ENDO-205 investigational new drug application for endometriosis — Contemporary OB/GYN, March 23, 2026. https://www.contemporaryobgyn.net/view/fda-clears-endo-205-investigational-new-drug-application-for-endometriosis
- Novel, Non-hormonal Therapeutic for Endometriosis, NIH grant 1SB1HD118921-01 (funded work, not findings) — NIH RePORTER, 2025. https://reporter.nih.gov/project-details/11186444
- Is this the first disease-modifying treatment for endometriosis? — Drug Discovery News, 2026. https://www.drugdiscoverynews.com/is-this-the-first-disease-modifying-treatment-for-endometriosis-17177
- Novel, Non-hormonal Therapeutic for Endometriosis, NIH grant 1R44HD100289-01 (funded work, not findings) — NIH RePORTER, 2019. https://reporter.nih.gov/project-details/9846678
